Mikhail Blagosklonny Education and Work History

Mikhail Blagosklonny attended the First Pavlov state Medical University of St. Petersburg. It is the place where he attained both his M.D and Ph.D. in experimental medicine and cardiology. Blagosklonny has since then been practicing medicine in various areas with a specification in cancer and aging. It has given him the expertise in the field too.

Blagosklonny was hired as an associate professor of Medicine at the New York Medical College in 2002.He was also a senior scientist at the Ordway Research Institute. He only served there till 2009 where he found a gateway to the Roswell Park Cancer Institute where he became the professor of oncology. Visit ResearchGate to keep up to date with Mikhail’s latest work.

During his studies, Mikhail Blagosklonny was keen in the search for the particular cancer therapies that help and protects healthy cells from damage by radioactive rays and chemotherapy. He also enrolled in studies that show the aging mechanism and the anti-aging treatment too. Other researchers that he was interested in are the molecular and cellular clinical and biology investigations. His research includes cellular senescence, cell cycle, signal transduction and anti- cancer therapeutics.

Mikhail Blagosklonny’s passion for aging and cancer study drove him to postulated theory of the likely role of TOR in aging and disease. Therefore, proposed that a cancer drug called rapamycin can be used as the treatment for a person’s life extension. Among other things, Mikhail has been doing editorial work for several journals as the chief author.

Some of the journals include aging, oncotarget and cell cycle. Also at the biology and cancer therapy, Mikhail serves as a junior editor. Also, Blagosklonny has written over 170 journals and research articles. Among all those journals he has also been the founding and chief editor for several others. At Roswell Park Cancer Institute, Mikhail extensive knowledge and information about cancer and aging is very significant.

It is because the institution deals on sharing possible approaches and ideas on how to curb the disease. Some of the institutional plans include how slowing down aging can prevent cancer and tissue- specific therapy cancer. Therefore, with Blagosklonny impact in the institute, it will be easy for them to come up with a solution faster than they would have anticipated. Follow Mikhail on Google Scholar

Leave a Reply

Your email address will not be published. Required fields are marked *